Imba Iphase DS8201A

Iphase DS8201A

Tsananguro pfupi:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Kusangana izvozvi Wedzera mungoro yekutengera

Chigadzirwa Chinhu

Zvigadzirwa tags

Kunyora kwechigadzirwa DS - 8201A, inozivikanwawo seTrastuzumab Deruxtecan (T - DXD), is Anti Boyd - Doll Conjugate (Adc) Yakagadzirirwa Kurapa kweHer2 - Vanogona Kugona. Inosanganisa a Her2 - Inotarisira Monoclonal Anti Body (yakafanana neTrastuzumab) ine ipoisomerase yeTopoisomerese ini Inhibitor (Deruxtecan) seCytotoxic Paraload. Mushonga unonunura chomotherapy zvakananga kumasokisi cancer achiratidza her her2, achivandudza kushanda kwemhedzisiro apo kudzikamisa kukuvadzwa kwemasero akajairwa.

Chikamu:
Cathepsin
Item kwete:
015200.02
Saizi yuniti:
200ul, 2mg / ml
Tishu:
N / a
Marudzi:
N / a
Mamiriro ekuchengetedza uye kufambisa:
Chitoro they - 70 ° C. Ice yakaoma.